Tyrosine kinases regulate intracellular calcium during alpha(2)-adrenergic contraction in rat aorta

Am J Physiol Heart Circ Physiol. 2002 Oct;283(4):H1673-80. doi: 10.1152/ajpheart.01034.2001.

Abstract

We have demonstrated enhanced contractile sensitivity to the alpha(2)-adrenoreceptor (alpha(2)-AR) agonist UK-14304 in arteries from rats made hypertensive with chronic nitric oxide synthase (NOS) inhibition (LHR) compared with arteries from normotensive rats (NR); additionally, this contraction requires Ca(2+) entry. We hypothesized that tyrosine kinases augment alpha(2)-AR contraction in LHR arteries by increasing Ca(2+). The tyrosine kinase inhibitor tyrphostin 23 significantly attenuated UK-14304 contraction of denuded thoracic aortic rings from NR and LHR. However, tyrphostin 23 did not alter UK-14304 contraction in ionomycin-permeabilized aorta, which indicates that tyrosine kinases regulate intracellular Ca(2+) concentration. The Src family inhibitor PP1 and the epidermal growth factor receptor kinase inhibitor AG-1478 did not alter alpha(2)-AR contraction, whereas the mitogen-activated protein kinase extracellular signal-regulated kinase kinase inhibitor PD-98059 attenuated the contraction. Contraction to CaCl(2) in ionomycin-permeabilized LHR rings was greater than in NR rings. UK-14304 augmented CaCl(2) contraction in ionomycin-permeabilized rings from both groups but to a greater extent in LHR aorta. Together, these data suggest that alpha(2)-AR stimulates contraction via two pathways. One, which is enhanced with NOS inhibition hypertension, activates Ca(2+) sensitivity and is independent of tyrosine kinases. The other is tyrosine kinase dependent and regulates intracellular Ca(2+) concentration.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adrenergic alpha-Agonists / pharmacology
  • Animals
  • Aorta / physiology*
  • Brimonidine Tartrate
  • Calcium / metabolism*
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology
  • Hypertension / metabolism
  • Male
  • Mitogen-Activated Protein Kinases / metabolism
  • Muscle Contraction / drug effects
  • Muscle Contraction / physiology
  • Muscle, Smooth, Vascular / enzymology*
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Protein-Tyrosine Kinases / metabolism*
  • Pyrazoles / pharmacology
  • Pyrimidines / pharmacology
  • Quinazolines
  • Quinoxalines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, alpha-2 / metabolism*
  • Tyrphostins / pharmacology

Substances

  • 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine
  • Adrenergic alpha-Agonists
  • Enzyme Inhibitors
  • Flavonoids
  • Pyrazoles
  • Pyrimidines
  • Quinazolines
  • Quinoxalines
  • Receptors, Adrenergic, alpha-2
  • Tyrphostins
  • RTKI cpd
  • Brimonidine Tartrate
  • Nitric Oxide Synthase
  • Protein-Tyrosine Kinases
  • Mitogen-Activated Protein Kinases
  • tyrphostin A23
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Calcium